South Korea · Delayed Price · Currency is KRW Pharos iBio Company Description
Pharos iBio Co., Ltd. develops treatments for rare and refractory diseases using AI based drug development platform in South Korea.
It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of platinum-resistant/refractory ovarian cancer; PHI-101-TNBC for the treatment of metastatic triple-negative breast cancer; PHI-101-RS, a radiation sensitizer; PHI-201, a K-Ras hub-protein inhibitor; PHI-301, a FAK hub-protein inhibitor for the treatment of metastatic cancer; PHI-401, an anaplastic lymphoma kinase (ALK) protein inhibitor; and PHI-501 a pan-RAF/DDRs inhibitor.
The company was founded in 2016 and is headquartered in Anyang-Si, South Korea.
| Country | South Korea |
| Founded | 2016 |
| Industry | Pharmaceutical Preparations |
| CEO | Jeong Hyeok Yoon |
Contact Details
Address: 1407&1408, 38, Heungan-daero Anyang-Si South Korea | |
| Phone | 82 3 1345 6170 |
| Website | pharosibio.com |
Stock Details
| Ticker Symbol | 388870 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeong Hyeok Yoon | Chief Executive Officer |
| Sung Won Moon | Chief Financial Officer |